HOMEAssociate Professor Hirotomo Yamanashi

Faculty

Associate Professor Hirotomo Yamanashi

Speciality / Research theme / Keywords
General medicine, Clinical infectious disease
frailty, Sarcopenia, Multimorbidity and chronic infectious diseases
Supervision
Masters ProgrammeDoctoral Programme

Qualifications

MD, PhD

Personal/work Web page addresses

http://www.mh.nagasaki-u.ac.jp/soshin/ http://www.tm.nagasaki-u.ac.jp/internal/

Affiliation(s)

Department of General Medicine, Nagasaki University Graduate School of Biomedical Sciences Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University Department of General Medicine/ Infectious Diseases, Nagasaki University Hospital

Background

  • 2021-Present Associate Professor of Department of General Medicine
  • 2018-2021 Senior lecturer of Department of General Medicine (Japan Disaster Relief Infectious Diseases Response Team in 2019)
  • 2013-2018 Assistant professor of Department of Island and Community Medicine (Médecins Sans Frontières in 2016, 2017)
  • 2012-2013 Staff doctor of Department of Infectious Diseases, Nagasaki University Hospital
  • 2011-2012 Director of Ohi Kyodo Clinic
  • 2008-2011 Senior Resident of Centre for Family Medicine Development Tokyo
  • 2006-2008 Junior Doctor of Yokosuka Uwamachi General Hospital

Teaching

Giving lectures (General Medicine, Infectious diseases, and Community Health) in TMGH, Nagasaki University Graduate School of Biomedical Sciences and Nagasaki University Hospital. Supervisor of Joint Nagasaki-LSHTM PhD Programme.

Research

I have been studying epidemiological studies in Vietnam, India, and Japan, particularly on primary care, geriatric medicine, clinical infectious diseases. I have participated in Nagasaki Islands Study since 2014, which is a prospective cohort study aiming to investigate genetic susceptibility to atherosclerosis, cardiovascular diseases, rheumatoid arthritis, and frail & sarcopenia. I am also engaged in international study collaborating with the Andhra Pradesh Children and Parents Study (PI: Professor Sanjay Kinra, LSHTM).

The country/countries where you work currently

Goto City, Nagasaki, Japan/ Hyderabad, India

Five MOST IMPORTANT/INTERESTING recent publications

  1. Miyata J, Yamanashi H, Dake Y, Nobusue K, Doi Y, Honda Y, Nonaka F, Arima K, Tamai M, Sasaki D, Shimizu Y, Hasegawa H, Kitaoka T, Yanagihara K, Aoyagi K, Kawakami A, Maeda T. Period prevalence of uveitis in human T-lymphotropic virus 1 carriers versus noncarriers in a highly endemic area: The Nagasaki Islands Study. J Med Virol. 2024; 96(5):e29653.
  2. Xu Q, Nabeshima T, Hamada K, Sugimoto T, Tun MMN, Morita K, Yamanashi H, Maeda T, Ariyoshi K, Takamatsu Y. Transmission of Severe Fever with Thrombocytopenia Syndrome Virus to Human from Nonindigenous Tick Host, Japan. Emerg Infect Dis. 2024; 30(11):2419-2423.
  3. Miyata J, Yamanashi H, Kawashiri SY, Soutome S, Arima K, Tamai M, Nonaka F, Honda Y, Kitamura M, Yoshida K, Shimizu Y, Hayashida N, Kawakami S, Takamura N, Sawase T, Yoshimura A, Nagata Y, Ohnishi M, Aoyagi K, Kawakami A, Saito T, Maeda T. Profile of Nagasaki Islands Study (NaIS): A Population-based Prospective Cohort Study on Multi-disease. J Epidemiol. 2024; 34(5):254-263.
  4. Yamanashi H, Nobusue K, Nonaka F, Honda Y, Shimizu Y, Kawashiri SY, Izumida M, Kubo Y, Tamai M, Nagata Y, Yanagihara K, Kulkarni B, Kinra S, Kawakami A, Maeda T. Human T-cell lymphotropic virus type-1 infection associated with sarcopenia: community-based cross-sectional study in Goto, Japan. Aging (Albany NY). 2020; 12(15):15504-15513.
  5. Yamanashi H, Koyamatsu J, Nagayoshi M, Shimizu Y, Kawashiri SY, Kondo H, Fukui S, Tamai M, Sato S, Yanagihara K, Kawakami A, Maeda T. Human T-Cell Leukemia Virus-1 Infection Is Associated With Atherosclerosis as Measured by Carotid Intima-Media Thickness in Japanese Community-Dwelling Older People. Clin Infect Dis. 2018; 67(2):291-294. 

Message

Emerging problems in the super-aged society is age-related functional decline, such as frailty, sarcopenia, and multimorbidity. I am keen to know how we can describe age-related functional decline in each community, and how we can respond to these issues globally in aspects of both clinical medicine and public health.

PAGE TOP